openPR Logo
Press release

Ataxia Telangiectasia Market to Witness Growth by 2032 | Matrix Biomed, IntraBio Inc, EryDel, Acasti Pharma, expected to boost the market

12-08-2023 12:23 PM CET | Health & Medicine

Press release from: DelveInsight Business Research LLP

Ataxia Telangiectasia Market

Ataxia Telangiectasia Market

DelveInsight's "Ataxia Telangiectasia Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of Ataxia Telangiectasia, historical and forecasted epidemiology as well as the Ataxia Telangiectasia market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan.

The Ataxia Telangiectasia market report provides current treatment practices, emerging drugs, the market share of the individual therapies, and the current and forecasted Ataxia Telangiectasia market size from 2019 to 2032, segmented by seven major markets. The Report also covers current Ataxia Telangiectasia treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best opportunities and assesses the underlying potential of the Ataxia Telangiectasia market.

Request for a Free Sample Report @ https://www.delveinsight.com/sample-request/ataxia-telangiectasia-at-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Ataxia Telangiectasia Overview

Ataxia telangiectasia (A-T) is a rare, genetic, and progressive neurological disorder that primarily affects the nervous system, immune system, and other body systems. It's caused by mutations in the ATM gene, which plays a crucial role in repairing damaged DNA within cells.
Key characteristics and features of ataxia telangiectasia include:
Neurological Symptoms: A-T typically presents with progressive cerebellar ataxia, which affects coordination, balance, and movement control. Children with A-T often experience difficulty walking, unsteadiness, involuntary jerking movements (called chorea), and a tremor. Speech difficulties may also develop due to muscle control problems.
Oculocutaneous Telangiectasia: A distinctive feature of A-T is the presence of dilated blood vessels close to the surface of the skin and in the whites of the eyes (telangiectasias). These small red spider-like clusters of blood vessels can appear in various parts of the body, particularly on the cheeks and ears.
Immune System Compromises: A-T leads to immune system deficiencies, making affected individuals more susceptible to infections, particularly respiratory infections. Recurrent respiratory infections are common and can be severe.
Increased Cancer Risk: A-T is associated with an increased risk of certain cancers, particularly leukemia and lymphoma, due to the compromised DNA repair mechanism. However, not every individual with A-T develops cancer.
Other Health Issues: Some individuals with A-T may experience delayed growth, respiratory issues, sensitivity to ionizing radiation, and increased risk of developing diabetes or other metabolic disorders.
Diagnosis of A-T involves a combination of clinical evaluation, physical examination to identify characteristic features like telangiectasias, and genetic testing to confirm mutations in the ATM gene.
Unfortunately, there is no cure for ataxia telangiectasia. Treatment is generally focused on managing symptoms and complications. Physical and occupational therapy may help with maintaining mobility and addressing muscle weakness. Management of infections and regular monitoring for potential complications, including cancer surveillance, are crucial aspects of care.
Due to its complex nature, management of ataxia telangiectasia often involves a multidisciplinary approach with input from neurologists, immunologists, geneticists, and other specialists to provide comprehensive care and support for affected individuals and their families.

Learn more about Ataxia Telangiectasia, treatment algorithms in different geographies, and patient journeys. Contact to receive a sample @ https://www.delveinsight.com/report-store/ataxia-telangiectasia-at-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Ataxia Telangiectasia Market

The Ataxia Telangiectasia market outlook of the report helps to build a detailed comprehension of the historical, current, and forecasted Ataxia Telangiectasia market trends by analyzing the impact of current Ataxia Telangiectasia therapies on the market and unmet needs, and drivers, barriers, and demand for better technology.

This segment gives a thorough detail of the Ataxia Telangiectasia market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated Ataxia Telangiectasia market data are presented with relevant tables and graphs to give a clear view of the market at first sight.

According to DelveInsight, the Ataxia Telangiectasia market in 7MM is expected to witness a major change in the study period 2019-2032.

Request a sample and discover more about the report offerings at:
https://www.delveinsight.com/sample-request/ataxia-telangiectasia-at-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Ataxia Telangiectasia Epidemiology

The Ataxia Telangiectasia epidemiology section provides insights into the historical and current Ataxia Telangiectasia patient pool and forecasted trends for seven individual major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the Ataxia Telangiectasia market report also provides the diagnosed patient pool, trends, and assumptions.

Explore more about Ataxia Telangiectasia Epidemiology at: https://www.delveinsight.com/report-store/ataxia-telangiectasia-at-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Ataxia Telangiectasia Drugs Uptake

This section focuses on the uptake rate of the potential Ataxia Telangiectasia drugs recently launched in the Ataxia Telangiectasia market or expected to be launched in 2019-2032. The analysis covers the Ataxia Telangiectasia market uptake by drugs, patient uptake by therapies, and sales of each drug.

Ataxia Telangiectasia Drugs Uptake helps in understanding the drugs with the most rapid uptake and the reasons behind the maximal use of new drugs and allows the comparison of the drugs based on Ataxia Telangiectasia market share and size, which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

Ataxia Telangiectasia Pipeline Development Activities

The Ataxia Telangiectasia report provides insights into different therapeutic candidates in Phase II, and Phase III stages. It also analyses Ataxia Telangiectasia key players involved in developing targeted therapeutics.

Request for a sample report to understand more about the Ataxia Telangiectasia pipeline development activities at: https://www.delveinsight.com/sample-request/ataxia-telangiectasia-at-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Ataxia Telangiectasia Therapeutics Assessment

Major key companies are working proactively in the Ataxia Telangiectasia Therapeutics market to develop novel therapies which will drive the Ataxia Telangiectasia treatment markets in the upcoming years.

Learn more about the emerging therapies & key companies at: https://www.delveinsight.com/report-store/ataxia-telangiectasia-at-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Ataxia Telangiectasia Report Key Insights

1. Ataxia Telangiectasia Patient Population
2. Ataxia Telangiectasia Market Size and Trends
3. Key Cross Competition in the Ataxia Telangiectasia Market
4. Ataxia Telangiectasia Market Dynamics (Key Drivers and Barriers)
5. Ataxia Telangiectasia Market Opportunities
6. Ataxia Telangiectasia Therapeutic Approaches
7. Ataxia Telangiectasia Pipeline Analysis
8. Ataxia Telangiectasia Current Treatment Practices/Algorithm
9. Impact of Emerging Therapies on the Ataxia Telangiectasia Market

Table of Contents

1. Key Insights
2. Executive Summary
3. Ataxia Telangiectasia Competitive Intelligence Analysis
4. Ataxia Telangiectasia Market Overview at a Glance
5. Ataxia Telangiectasia Disease Background and Overview
6. Ataxia Telangiectasia Patient Journey
7. Ataxia Telangiectasia Epidemiology and Patient Population
8. Ataxia Telangiectasia Treatment Algorithm, Current Treatment, and Medical Practices
9. Ataxia Telangiectasia Unmet Needs
10. Key Endpoints of Ataxia Telangiectasia Treatment
11. Ataxia Telangiectasia Marketed Products
12. Ataxia Telangiectasia Emerging Therapies
13. Ataxia Telangiectasia Seven Major Market Analysis
14. Attribute Analysis
15. Ataxia Telangiectasia Market Outlook (7 major markets)
16. Ataxia Telangiectasia Access and Reimbursement Overview
17. KOL Views on the Ataxia Telangiectasia Market
18. Ataxia Telangiectasia Market Drivers
19. Ataxia Telangiectasia Market Barriers
20. Appendix
21. DelveInsight Capabilities
22. Disclaimer

Get the Detailed TOC of the Ataxia Telangiectasia Market report here: https://www.delveinsight.com/report-store/ataxia-telangiectasia-at-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Contact Us:

Kritika Rehani
info@delveinsight.com
+91-9650213330
www.delveinsight.com

About DelveInsight

DelveInsight is a leading Life Science market research and business consulting company recognized for its off-the-shelf syndicated market research reports and customized solutions to firms in the healthcare sector.

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Ataxia Telangiectasia Market to Witness Growth by 2032 | Matrix Biomed, IntraBio Inc, EryDel, Acasti Pharma, expected to boost the market here

News-ID: 3320970 • Views:

More Releases from DelveInsight Business Research LLP

Tirzepatide Market Size and Share Across 7MM and Competitive Landscape by DelveInsight | Key Players - Eli Lilly and Company
Tirzepatide Market Size and Share Across 7MM and Competitive Landscape by DelveI …
DelveInsight has released a comprehensive report titled "Tirzepatide Market Forecast" offering a thorough examination and predictive insights into the Tirzepatide market landscape until 2032 across the seven major markets (7MM), encompassing the United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan. The extensive report offers a thorough examination of the market potential and market share of Tirzepatide in the therapeutics landscape for Obesity across the 7MM, spanning
SAXENDA (Liraglutide) Market Size and Share Across 7MM and Competitive Landscape by DelveInsight | Key Players - Novo Nordisk
SAXENDA (Liraglutide) Market Size and Share Across 7MM and Competitive Landscape …
DelveInsight has released a comprehensive report titled "SAXENDA (Liraglutide) Market Forecast" offering a thorough examination and predictive insights into the SAXENDA (Liraglutide) market landscape until 2032 across the seven major markets (7MM), encompassing the United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan. The extensive report offers a thorough examination of the market potential and market share of SAXENDA (Liraglutide) in the therapeutics landscape for Obesity across
High-Grade Glioma Pipeline Analysis Covering Clinical Trials, Emerging Therapies, FDA, EMA, and PMDA Approvals, Competitive Landscape | BioMimetix, Oblato, PTC Therapeutics, Lee's Pharmaceutical, Nuvation Bio, Laminar Pharma, Basilea Pharma
High-Grade Glioma Pipeline Analysis Covering Clinical Trials, Emerging Therapies …
As per DelveInsight's assessment, globally, about 150+ key pharma and biotech companies are working on 150+ pipeline drugs in the High-Grade Glioma therapeutics landscape based on different Routes of Administration (ROA), Mechanism of Action (MOA), and molecule types. Several of the therapies are in the advanced stages of clinical development and are expected to launch in the coming years. "High-Grade Glioma Pipeline Insight, 2024" report by DelveInsight provides a comprehensive analysis
Duchenne Muscular Dystrophy (DMD) Pipeline Analysis Covering Clinical Trials, Emerging Therapies, FDA, EMA, and PMDA Approvals, Competitive Landscape | Capricor Therapeutics (CAP-1002), Santhera, Sarepta, Italfarmaco, FibroGen, Pfizer, Daiichi Sankyo
Duchenne Muscular Dystrophy (DMD) Pipeline Analysis Covering Clinical Trials, Em …
Las Vega (Nevada), United States //- As per DelveInsight's assessment, globally, about 75+ key pharma and biotech companies are working on 75+ pipeline drugs in the Duchenne Muscular Dystrophy therapeutics landscape based on different Routes of Administration (ROA), Mechanism of Action (MOA), and molecule types. Several of the therapies are in the advanced stages of clinical development and are expected to launch in the coming years. "Duchenne Muscular Dystrophy Pipeline Insight"

All 5 Releases


More Releases for Ataxia

Ataxia Therapeutics Pipeline Analysis 2018 | Reata Pharmaceuticals, Inc., Voyage …
Ataxia is a type of movement disorder characterized by lack of muscle control or coordination of voluntary movements. Some of the symptoms observed in the patients with ataxia are poor coordination, change in speech, difficulty in swallowing, and unsteady walk. Download the sample report @ https://www.pharmaproff.com/request-sample/1078 The disease causes include head injury; stroke; autoimmune diseases, such as sarcoidosis and multiple sclerosis; paraneoplastic syndromes; and viral infections. The disease is also found in
Ataxia Market: Surge in Alcohol Abuse and Sedentary Life Style Bolsters the Atax …
The United States of America is marred by ataxia as more than 150,000 cases have been found in the U.S.  The surge in the ataxia cases can be attributed to the food habits and the sedentary life style. Deficiency of vitamin B-12 is termed as one of the prominent causes of ataxia. Further, slurred speech, nystagmus (involuntary back and forth eye movement), problem in eating and writing, difficulty walking and
Friedreich's Ataxia Therapeutics - Pipeline Analysis, Clinical Trials & Results, …
the Friedreich's ataxia therapeutics pipeline comprises approximately 17 drug candidates in different stages of development. Friedreich’s ataxia is an autosomal recessive inherited genetic disorder that progressively damages the nervous system. Its initial symptoms include ataxia, impaired muscle coordination and impaired speech. This results in development of dysarthria, scoliosis, heart diseases and diabetes, but does not affect cognitive function. According to the research findings, most of the drug candidates in Friedreich's ataxia
Friedreich Ataxia (Central Nervous System) pipeline landscape H-1 (2017) - MRH
Friedreich ataxia (FA) is a neuromuscular disease that mainly affects the nervous system and the heart. FA is a hereditary disease, caused by a defective gene that can be passed down through a family. Signs and symptoms include ataxia, weakness, and spasticity, sensory impairment, skeletal abnormalities, cardiac difficulties and diabetes. Request Free Sample Report: http://www.marketresearchhub.com/enquiry.php?type=S&repid=1063542 Report Highlights Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Friedreich Ataxia - Pipeline Review, H1
Global Treatments for Syndromes of Progressive Ataxia and Weakness Disorders Mar …
The Syndromes Progressive Ataxia Weakness Disorders Market report provides in-depth analysis of parent market trends, macro-economic indicators and governing factors along with market attractiveness as per segments. The report also maps the qualitative impact of various market factors on market segments and geographies. Ataxia is a neurological condition, characterized by lack of voluntary coordination of muscle movement. Ataxia causes head trauma, stroke, Transient Ischemic Attack (TIA), tumor and toxic reaction. Progressive
Discover the Global Cerebellar Ataxia Clinical Trials Review, H2, 2016
MarketResearchReports.Biz presents this most up-to-date research on “ Cerebellar Ataxia Global Clinical Trials Review, H2, 2016 ” GlobalData's clinical trial report, Cerebellar Ataxia Global Clinical Trials Review, H2, 2016" provides an overview of Cerebellar Ataxia clinical trials scenario. This report provides top line data relating to the clinical trials on Cerebellar Ataxia. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The